Recent Quotes
My Watchlist
Indicators
Markets
Stocks
Funds
Overview
Currencies
International
Treasuries

Lineage Cell Therapeutics, Inc. Common Stock (NY:LCTX)

1.555 +0.075 (+5.07%)
Streaming Delayed Price Updated: 3:04 PM EDT, Mar 25, 2026 Add to My Watchlist
Quote
Overview Detailed Quote Charting Historical Prices
News
All News News Headlines Press Releases
Research
Quarterly Reports Insider Filings Other Filings

All News about Lineage Cell Therapeutics, Inc. Common Stock

< Previous 1 2 3 4 5 6 7 8 9 Next >
News headline image
Lineage Launches New Cell Therapy Program in Corneal Endothelial Disease
From Lineage Cell Therapeutics, Inc.
Via Business Wire
Lineage Cell Therapeutics (LCTX) Reports Q4 Revenue Beat and Narrowed Loss ↗
Via Chartmill
News headline image
Lineage Cell Therapeutics Reports Fourth Quarter and Full Year 2025 Financial Results and Provides Business Update
From Lineage Cell Therapeutics, Inc.
Via Business Wire
News headline image
Earnings Scheduled For November 6, 2025 ↗
 
Via Benzinga
News headline image
A Peek at Lineage Cell Therapeutics's Future Earnings ↗
 
Via Benzinga
News headline image
Lineage Cell Therapeutics to Report Fourth Quarter and Full Year 2025 Financial Results and Provide Business Update on March 5, 2026
From Lineage Cell Therapeutics, Inc.
Via Business Wire
News headline image
Lineage Takes Delivery of Gene-edited Hypoimmune Cell Line Under Partnership With Factor Bioscience
From Lineage Cell Therapeutics, Inc.
Via Business Wire
News headline image
Lineage Cell Therapeutics Issues Letter to Stockholders
From Lineage Cell Therapeutics, Inc.
Via Business Wire
News headline image
Lineage Cell Therapeutics Inc (NYSEARCA:LCTX) Reports Q3 2025 Earnings: Revenue Beat Overshadowed by Wider-Than-Expected Loss ↗
Lineage Cell Therapeutics reports Q3 2025 results with a revenue beat but a wider net loss. The company advances its cell therapy pipeline and has cash into 2027. 
Via Chartmill
News headline image
Lineage Cell Therapeutics Reports Third Quarter 2025 Financial Results and Provides Business Update
From Lineage Cell Therapeutics, Inc.
Via Business Wire
News headline image
Lineage Cell Therapeutics to Report Third Quarter 2025 Financial Results and Provide Business Update on November 6, 2025
From Lineage Cell Therapeutics, Inc.
Via Business Wire
News headline image
12 Health Care Stocks Moving In Monday's After-Market Session ↗
 
Via Benzinga
News headline image
Lineage Cell Therapeutics Initiates Cell Transplant Program In Type 1 Diabetes
From Lineage Cell Therapeutics, Inc.
Via Business Wire
News headline image
Lineage Cell Therapeutics to Present at September 2025 Investor Conferences
From Lineage Cell Therapeutics, Inc.
Via Business Wire
News headline image
5 Analysts Assess Lineage Cell Therapeutics: What You Need To Know ↗
 
Via Benzinga
News headline image
Lineage Announces Research Collaboration With William Demant Invest to Develop ReSonance™ (ANP1) for Hearing Loss
From Lineage Cell Therapeutics, Inc.
Via Business Wire
News headline image
12 Health Care Stocks Moving In Friday's Intraday Session ↗
 
Via Benzinga
News headline image
Lineage Cell Revenue Doubles in Q2 ↗
Via The Motley Fool
News headline image
Lineage Cell Therapeutics Inc. (NYSEARCA:LCTX) Reports Q2 2025 Revenue Beat but Wider Loss ↗
Lineage Cell Therapeutics Q2 2025: Revenue beats estimates at $2.77M (+84.6%), but net loss widens to -$0.13. Stock dips 4.95% amid clinical progress and cash runway into 2027. 
Via Chartmill
News headline image
Lineage Cell Therapeutics Reports Second Quarter 2025 Financial Results and Provides Business Update
From Lineage Cell Therapeutics, Inc.
Via Business Wire
News headline image
Earnings Scheduled For August 12, 2025 ↗
 
Via Benzinga
News headline image
Lineage Cell Therapeutics to Report Second Quarter 2025 Financial Results and Provide Business Update on August 12, 2025
From Lineage Cell Therapeutics, Inc.
Via Business Wire
News headline image
Two Biotech Stocks Poised For Big Moves On Monday ↗
 
Via Benzinga
News headline image
Lineage Cell Therapeutics Announces Updates to the 3rd Annual Spinal Cord Injury Investor Symposium
From Lineage Cell Therapeutics, Inc.
Via Business Wire
News headline image
Lineage Announces Dosing of First Patient in New Clinical Study of OPC1 for Subacute and Chronic Spinal Cord Injury
From Lineage Cell Therapeutics, Inc.
Via Business Wire
News headline image
Lineage to Present at 3rd Annual H.C. Wainwright BioConnect Investor Conference at Nasdaq NYC
From Lineage Cell Therapeutics, Inc.
Via Business Wire
News headline image
OpRegen® (RG6501) 36-Month Visual Acuity Results Featured at Clinical Trials at the Summit 2025
From Lineage Cell Therapeutics, Inc.
Via Business Wire
News headline image
Lineage Cell Therapeutics Reports First Quarter 2025 Financial Results and Provides Business Update
From Lineage Cell Therapeutics, Inc.
Via Business Wire
News headline image
Examining the Future: Lineage Cell Therapeutics's Earnings Outlook ↗
 
Via Benzinga
News headline image
Earnings Scheduled For May 13, 2025 ↗
 
Via Benzinga
< Previous 1 2 3 4 5 6 7 8 9 Next >
Stock Quote API & Stock News API supplied by www.cloudquote.io
Quotes delayed at least 20 minutes.
By accessing this page, you agree to the Privacy Policy and Terms Of Service.
© 2025 FinancialContent. All rights reserved.